CRIS Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals has a net margin of -446.05% compared to Curis's net margin of --. Curis's return on equity of -461.34% beat Armata Pharmaceuticals's return on equity of --.

Curis has a consensus price target of $16.33, signalling upside risk potential of 787.68%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $9.00 which suggests that it could grow by 281.36%. Given that Curis has higher upside potential than Armata Pharmaceuticals, analysts believe Curis is more attractive than Armata Pharmaceuticals.

Curis has a beta of 3.605, which suggesting that the stock is 260.513% more volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.224%.

Curis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curis pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Curis quarterly revenues are $2.4M, which are larger than Armata Pharmaceuticals quarterly revenues of --. Curis's net income of -$10.6M is lower than Armata Pharmaceuticals's net income of -$6.5M. Notably, Curis's price-to-earnings ratio is -- while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curis is 1.15x versus 1,016.56x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -446.05% compared to Curis's net margin of --. Curis's return on equity of -461.34% beat Perspective Therapeutics's return on equity of --.

Curis has a consensus price target of $16.33, signalling upside risk potential of 787.68%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.1071 which suggests that it could grow by 241.58%. Given that Curis has higher upside potential than Perspective Therapeutics, analysts believe Curis is more attractive than Perspective Therapeutics.

Curis has a beta of 3.605, which suggesting that the stock is 260.513% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.701%.

Curis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curis pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Curis quarterly revenues are $2.4M, which are larger than Perspective Therapeutics quarterly revenues of --. Curis's net income of -$10.6M is higher than Perspective Therapeutics's net income of -$18.2M. Notably, Curis's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curis is 1.15x versus 29.11x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Mustang Bio has a net margin of -446.05% compared to Curis's net margin of --. Curis's return on equity of -461.34% beat Mustang Bio's return on equity of --.

Curis has a consensus price target of $16.33, signalling upside risk potential of 787.68%. On the other hand Mustang Bio has an analysts' consensus of -- which suggests that it could grow by 4210.35%. Given that Mustang Bio has higher upside potential than Curis, analysts believe Mustang Bio is more attractive than Curis.

Curis has a beta of 3.605, which suggesting that the stock is 260.513% more volatile than S&P 500. In comparison Mustang Bio has a beta of 2.165, suggesting its more volatile than the S&P 500 by 116.485%.

Curis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mustang Bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curis pays -- of its earnings as a dividend. Mustang Bio pays out -- of its earnings as a dividend.

Curis quarterly revenues are $2.4M, which are larger than Mustang Bio quarterly revenues of --. Curis's net income of -$10.6M is lower than Mustang Bio's net income of -$153K. Notably, Curis's price-to-earnings ratio is -- while Mustang Bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curis is 1.15x versus -- for Mustang Bio. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -446.05% compared to Curis's net margin of -35.79%. Curis's return on equity of -461.34% beat Protalix BioTherapeutics's return on equity of 10.9%.

Curis has a consensus price target of $16.33, signalling upside risk potential of 787.68%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 833.33%. Given that Protalix BioTherapeutics has higher upside potential than Curis, analysts believe Protalix BioTherapeutics is more attractive than Curis.

Curis has a beta of 3.605, which suggesting that the stock is 260.513% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.227, suggesting its less volatile than the S&P 500 by 122.694%.

Curis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curis pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Curis quarterly revenues are $2.4M, which are smaller than Protalix BioTherapeutics quarterly revenues of $10.1M. Curis's net income of -$10.6M is lower than Protalix BioTherapeutics's net income of -$3.6M. Notably, Curis's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 37.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curis is 1.15x versus 2.10x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.